Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model

: Jablonka, L.; Ashtikar, M.; Gao, G.F.; Thurn, M.; Modh, H.; Wang, J.-W.; Preuß, A.; Scheglmann, D.; Albrecht, V.; Röder, B.; Wacker, M.G.


European journal of pharmaceutics and biopharmaceutics 149 (2020), S.121-134
ISSN: 0939-6411
ISSN: 1873-3441
Fraunhofer IME ()

Over the years, the performance of the liposomal formulations of temoporfin, Foslip® and Fospeg®, was investigated in a broad array of cell-based assays and preclinical animal models. So far, little attention has been paid to the influence of drug release and liposomal stability on the plasma concentration–time profile. The drug release is a key attribute which impacts product quality and the in vivo efficacy of nanocarrier formulations. In the present approach, the in vitro drug release and the drug-protein transfer of Foslip® and Fospeg® was determined using the dispersion releaser technology. To analyze the stability of both formulations in physiological fluids, nanoparticle tracking analysis was applied. A comparable drug release behavior and a high physical stability with a vesicle size of approximately 92 ± 2 nm for Foslip® and at 111 ± 5 nm for Fospeg® were measured. The development of a novel hybrid in silico model resulted in an optimal representation of the in vivo data. Based on the information available for previous formulations, the model enabled a prediction of the performance of Foslip® in humans. To verify the simulations, plasma concentration–time profiles of a phase I clinical trial were used. An absolute average fold error of 1.4 was achieved. Moreover, a deconvolution of the pharmacokinetic profile into different fractions relevant for the in vivo efficacy and safety was achieved. While the total plasma concentration reached a cmax of 2298 ng/mL after 0.72 h, the monomolecular drug accounted for a small fraction of the photosensitizer with a cmax of 321 ng/mL only.